Skip to main content

Irlab Therapeutics

IRLAB Therapeutics AB is a Swedish clinical-stage biopharmaceutical company focused on treatments for Parkinson's disease and neurodegenerative disorders. The company discovers and develops drug candidates using its proprietary Integrative Screening Process technology platform, advancing lead candidates including mesdopetam and pirepemat. Main revenue drivers currently consist of strategic pharmaceutical research collaborations, milestone grants, licensing fees, and equity financing as clinical trials progress. IRLAB Therapeutics targets clinical research institutions, neurology specialists, global pharmaceutical partners, and Parkinson's disease patients across Europe and North America. The company holds a specialized niche position in Swedish CNS drug discovery and neurodegenerative disease research. Headquartered in Gothenburg, Sweden, IRLAB Therapeutics AB is listed on Nasdaq Stockholm.

2 of the funds FundTelligence covers report a position in Irlab Therapeutics.

Legal name
Irlab Therapeutics AB
Sector
Health Care
Country
Sweden
Funds holding it
2
Exposure themes
Ageing & Longevity, Age-Related Disease, Neurodegeneration

Funds holding Irlab Therapeutics

Loading...